CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2008-07-16): Rituximab therapy for systemic vasculitis restores immune cell homeostasis

Clinical

Rituximab therapy for systemic vasculitis restores immune cell homeostasis

Last Updated: 2008-07-16 15:26:04 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Treatment with rituximab leads to restoration of peripheral B- and T-lymphocyte homeostasis in patients with mixed cryoglobulinemia vasculitis, according to French researchers.

In the June 1st issue of Blood, Dr. Patrice Cacoub of Universite Pierre et Marie Curie, Paris and colleagues note that chronic infection with hepatitis C virus (HCV) is the main cause of this potentially life-threatening systemic vasculitis.

Although rituximab has been used to successfully treat the disorder, they add, little is known about the processes involved.

To investigate, the team studied 21 patients with HCV-related mixed cryoglobulinemia, of whom 14 achieved a complete response to rituximab. Also included were 50 healthy controls and 20 HCV patients without serum cryoglobulin and vasculitis.

Before treatment, the vasculitis patients showed significantly reduced naive B cells and CD4+CD25+FoxP3 regulatory T cells. Memory B cells were increased as were plasmablasts.

At 12 months or more after rituximab treatment and subsequent immune reconstitution, these abnormalities were reversed.

Patients who had a complete response showed a significant expansion of regulatory T cells and a significant decrease in CD8 T-cell activation. Both IL-12 and interferon-gamma production were significantly decreased.

The results, the researchers conclude, show that "B-cell depletion with rituximab dramatically improves abnormalities in B-cell homeostasis." Furthermore, "B-cell depletion may be an efficient therapy not only because it reduces or abolishes the hyperproduction of cryoglobulin, but also because this treatment improves T-cell homeostasis in restoring the regulation/activation and Th1/Th2 imbalances."

Blood 2008;111:5334-5341.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.